Thursday, September 18, 2014 6:20:45 AM
Chuckles;
caveat; I am not a scientist, and I'm not qualified to express a scientific opinion. I'm more like a reporter / librarian . What I can say is what I observe from the literature.
Both DHA and EPA are metabolically active and essential to "normal" body functions. DHA oriented studies consistently point to its primary activity as being utilized in the brain, especially during early development . That's because DHA is found in larger amounts in the brain vs EPA, there but even at that , there are questions of which fatty acid is utilized by the brain because some postulate that EPA isn't seen in the brain as much because it is being utilized more than DHA. Literature also suggests EPA has an anti depressant like effect (& confirmed by many here) so we know its biologically active in the brain. So DHA is net beneficial for your body in dietary levels (from foods). And in low dose it's hard to tell the difference between the two
But what we are focused on is very high dose of either. 4 grams of either EPA / DHA is a lot to take daily , roughly same as taking 20-30 OTC supplements daily. And that is where EPA clearly pulls away from DHA. In high dose, both are effective in lowering TGs other lipds, but in high Doses, EPA perform much better than DHA such as not raising LDL-C. In addition there are fewer side effects of pure EPA vs DHA in high doses. So I believe Vascepa is highly differentiated , and more so than any other O3 formulated drug including Lovaza and up and coming Epanova.
Then remember this, No other O3 drug is as far along in an outcomes trials like Reduce It. If Vascepa performs close to JELIS cohort, why would any doc mess around with anything less than pure EPA -when it becomes proven to reduce CVD risk? Layer on patent protection til 2030 and you have a very valuable asset . BTW they have patents to cover DHA along with EPA to 20%. So they built a nice "fire-wall"
Lastly, an area of O3 science that is emerging deals with discovery those specific metabolites of EPA that are responsible for its heart benefits. Thsi recently came to light in a JAMA article last month (EPA Metabolite 18-HEPE) http://jama.jamanetwork.com/article.aspx?articleid=1900498
Example of the direction of EPA related science: There is a study at Penn State in which researchers isolated a specific EPA metabolite and are using it to CURE leukemia in mice ( yes I said cure) http://www.news-medical.net/news/20111223/D12-PGJ3-compound-can-cure-leukemia.aspx
Now imagine a day when, instead of taking 4 large capsules of Vascepa, you can take 1 pill contain the active EPA metabolites? Imagine after Reduce It, Amarin (under protection of its combo patents) comes out with statin drug combined with a few of these metabolites in a single daily dose?
Now that would be something wouldn't it? Hard to call lit "fish Oil" at that point... and any comparison with DHA becomes moot
caveat; I am not a scientist, and I'm not qualified to express a scientific opinion. I'm more like a reporter / librarian . What I can say is what I observe from the literature.
Both DHA and EPA are metabolically active and essential to "normal" body functions. DHA oriented studies consistently point to its primary activity as being utilized in the brain, especially during early development . That's because DHA is found in larger amounts in the brain vs EPA, there but even at that , there are questions of which fatty acid is utilized by the brain because some postulate that EPA isn't seen in the brain as much because it is being utilized more than DHA. Literature also suggests EPA has an anti depressant like effect (& confirmed by many here) so we know its biologically active in the brain. So DHA is net beneficial for your body in dietary levels (from foods). And in low dose it's hard to tell the difference between the two
But what we are focused on is very high dose of either. 4 grams of either EPA / DHA is a lot to take daily , roughly same as taking 20-30 OTC supplements daily. And that is where EPA clearly pulls away from DHA. In high dose, both are effective in lowering TGs other lipds, but in high Doses, EPA perform much better than DHA such as not raising LDL-C. In addition there are fewer side effects of pure EPA vs DHA in high doses. So I believe Vascepa is highly differentiated , and more so than any other O3 formulated drug including Lovaza and up and coming Epanova.
Then remember this, No other O3 drug is as far along in an outcomes trials like Reduce It. If Vascepa performs close to JELIS cohort, why would any doc mess around with anything less than pure EPA -when it becomes proven to reduce CVD risk? Layer on patent protection til 2030 and you have a very valuable asset . BTW they have patents to cover DHA along with EPA to 20%. So they built a nice "fire-wall"
Lastly, an area of O3 science that is emerging deals with discovery those specific metabolites of EPA that are responsible for its heart benefits. Thsi recently came to light in a JAMA article last month (EPA Metabolite 18-HEPE) http://jama.jamanetwork.com/article.aspx?articleid=1900498
Example of the direction of EPA related science: There is a study at Penn State in which researchers isolated a specific EPA metabolite and are using it to CURE leukemia in mice ( yes I said cure) http://www.news-medical.net/news/20111223/D12-PGJ3-compound-can-cure-leukemia.aspx
Now imagine a day when, instead of taking 4 large capsules of Vascepa, you can take 1 pill contain the active EPA metabolites? Imagine after Reduce It, Amarin (under protection of its combo patents) comes out with statin drug combined with a few of these metabolites in a single daily dose?
Now that would be something wouldn't it? Hard to call lit "fish Oil" at that point... and any comparison with DHA becomes moot
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
